FindTrial
Sign In

To Evaluated the Influence of SARS-CoV-2 (COVID-19) Vaccine on the Outcomes of FET Cycle

To Evaluated the Influence of SARS-CoV-2 (COVID-19) Vaccine on the Outcomes of FET Cycle

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055597
Enrollment
Unknown
Registered
2022-01-14
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FET cycle

Interventions

SARS-CoV-2 vaccine group:None
No SARS-CoV-2 vaccine group:None

Sponsors

Sichuan Provincial Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.FET cycle; 2.Aged 20 to 40 years.

Exclusion criteria

Exclusion criteria: 1.PGT cycle; 2.Patients with uterine malformation, uterine adhesion, thin endometrium, repeated implantation failure, and recurrent abortion.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rates;—

Secondary

MeasureTime frame
Embryo fertilization rate;Live birth rate;Miscarriage rate;—

Countries

China

Contacts

Public ContactGong Yan

Sichuan Provincial Women's and Children's Hospital

gongyan_496181657@qq.com+86 15208393996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 9, 2026